Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC

Sign up for our daily newsletter

FDA approves Glaxo/Theravance drug for COPD lung disease

11:35 am by | 0 Comments

(Reuters) WASHINGTON - The Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both.

The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States. It consists of a corticosteroid, fluticasone furoate, and a novel long-acting beta-agonist, or LABA, called vilanterol. The product is inhaled through a palm-sized device called Ellipta.

The approval sent Theravance shares up 8.7 percent to $34.03 on the Nasdaq late on Friday morning.

(Reporting by Toni Clarke in Washington; editing by Matthew Lewis)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.